NASDAQ:FMTX Forma Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Forma Therapeutics Holdings Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $44.41 +0.72 (+1.65 %) (As of 09/22/2020 10:00 AM ET) Add Compare Share Today's Range$44.41Now: $44.41▼$44.8050-Day Range$32.95MA: $39.56▼$47.3352-Week Range$31.45Now: $44.41▼$50.00Volume191 shsAverage Volume199,126 shsMarket Capitalization$1.83 billionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsChartCompetitorsEarningsInstitutional OwnershipHeadlinesSocial Media Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing FT-2102, an oral selective small molecule investigational agent that is designed to bind to and inhibit mutated IDH1 enzymes, which is being evaluated in a Phase 2 trial for relapsed/refractory AML, as well as an exploratory Phase 1 trial for glioma; and FT-4101 and FT-8225, which are selective fatty acid synthase inhibitors. The company was founded in 2007 and is headquartered in Watertown, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingForma Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $56.25, Forma Therapeutics has a forecasted upside of 28.7% from its current price of $43.69.Amount of Analyst CoverageForma Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 4.0 Community Rank Outperform VotesForma Therapeutics has received 4 “outperform” votes. (Add your “outperform” vote.)Underperform VotesForma Therapeutics has received 1 “underperform” votes. (Add your “underperform” vote.)Community SentimentForma Therapeutics has received 80.00% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Forma Therapeutics and other stocks. Vote “Outperform” if you believe FMTX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe FMTX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldForma Therapeutics does not currently pay a dividend.Dividend GrowthForma Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Forma Therapeutics insiders have not sold or bought any company stock.Percentage Held by Institutions61.65% of the stock of Forma Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Forma Therapeutics are expected to grow in the coming year, from ($3.47) to ($2.91) per share. Previous Next Analyst Opinion: 3.5Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.83 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FMTX Previous Symbol CUSIPN/A CIKN/A Webwww.formatherapeutics.com Phone617-679-1970Debt Debt-to-Equity RatioN/A Current Ratio18.34 Quick Ratio18.34Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$100.56 million Price / Sales18.16 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees77 Outstanding Shares41,118,000Market Cap$1.83 billion Next Earnings Date11/12/2020 (Estimated) OptionableNot Optionable $44.41 +0.72 (+1.65 %) (As of 09/22/2020 10:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive FMTX News and Ratings via Email Sign-up to receive the latest news and ratings for FMTX and its competitors with MarketBeat's FREE daily newsletter. Forma Therapeutics (NASDAQ:FMTX) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of Forma Therapeutics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Forma Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Forma Therapeutics. When is Forma Therapeutics' next earnings date? Forma Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020. View our earnings forecast for Forma Therapeutics. How were Forma Therapeutics' earnings last quarter? Forma Therapeutics Holdings Inc (NASDAQ:FMTX) announced its quarterly earnings results on Thursday, August, 13th. The company reported ($4.58) EPS for the quarter, missing the consensus estimate of ($0.74) by $3.85. View Forma Therapeutics' earnings history. What price target have analysts set for FMTX? 4 Wall Street analysts have issued 1-year price targets for Forma Therapeutics' stock. Their forecasts range from $53.00 to $64.00. On average, they expect Forma Therapeutics' share price to reach $56.25 in the next twelve months. This suggests a possible upside of 26.7% from the stock's current price. View analysts' price targets for Forma Therapeutics. Who are some of Forma Therapeutics' key competitors? Some companies that are related to Forma Therapeutics include Novavax (NVAX), Acceleron Pharma (XLRN), Adaptive Biotechnologies (ADPT), Momenta Pharmaceuticals (MNTA), Crispr Therapeutics (CRSP), Iovance Biotherapeutics (IOVA), Allogene Therapeutics (ALLO), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Relay Therapeutics (RLAY), Denali Therapeutics (DNLI), Ablynx (ABLYF), Halozyme Therapeutics (HALO), bluebird bio (BLUE) and Fate Therapeutics (FATE). View all competitors. What other stocks do shareholders of Forma Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Forma Therapeutics investors own include Trade Desk (TTD), Boeing (BA), NVIDIA (NVDA), Okta (OKTA), Abbott Laboratories (ABT), Alibaba Group (BABA), CVS Health (CVS), Walt Disney (DIS), Gilead Sciences (GILD) and General Motors (GM). Who are Forma Therapeutics' key executives? Forma Therapeutics' management team includes the following people: Mr. Frank D. Lee, Pres, CEO & Director (Age 52)Mr. Todd E. Shegog, Sr. VP & CFO (Age 55)Dr. David N. Cook, Sr. VP & Chief Scientific Officer (Age 62)Dr. Jeannette Potts J.D., Ph.D., Sr. VP, Gen. Counsel & Corp. Sec. (Age 58)Ms. Mary E. Wadlinger, Sr. VP of Corp. Affairs & Chief HR Officer (Age 60) When did Forma Therapeutics IPO? (FMTX) raised $201 million in an initial public offering (IPO) on Friday, June 19th 2020. The company issued 11,800,000 shares at $16.00-$18.00 per share. Jefferies' SVB Leerink and Credit Suisse acted as the underwriters for the IPO. What is Forma Therapeutics' stock symbol? Forma Therapeutics trades on the NASDAQ under the ticker symbol "FMTX." When does the company's lock-up period expire? Forma Therapeutics' lock-up period expires on Wednesday, December 16th. Forma Therapeutics had issued 13,882,352 shares in its IPO on June 19th. The total size of the offering was $277,647,040 based on an initial share price of $20.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the expiration of the lock-up period. Who are Forma Therapeutics' major shareholders? Forma Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Cormorant Asset Management LP (8.66%), FMR LLC (4.34%), Logos Global Management LP (3.28%), Perceptive Advisors LLC (3.20%), Hillhouse Capital Advisors LTD. (1.28%) and Goldman Sachs Group Inc. (0.25%). Which institutional investors are buying Forma Therapeutics stock? FMTX stock was acquired by a variety of institutional investors in the last quarter, including Cormorant Asset Management LP, FMR LLC, Logos Global Management LP, Perceptive Advisors LLC, Hillhouse Capital Advisors LTD., Goldman Sachs Group Inc., Jane Street Group LLC, and Alyeska Investment Group L.P.. How do I buy shares of Forma Therapeutics? Shares of FMTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Forma Therapeutics' stock price today? One share of FMTX stock can currently be purchased for approximately $44.41. How big of a company is Forma Therapeutics? Forma Therapeutics has a market capitalization of $1.83 billion and generates $100.56 million in revenue each year. Forma Therapeutics employs 77 workers across the globe. What is Forma Therapeutics' official website? The official website for Forma Therapeutics is www.formatherapeutics.com. How can I contact Forma Therapeutics? Forma Therapeutics' mailing address is 500 ARSENAL STREET SUITE 100, WATERTOWN MA, 02472. The company can be reached via phone at 617-679-1970 or via email at [email protected] This page was last updated on 9/22/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
